ENYO Pharma Email Format
Biotechnology ResearchAuvergne-rhône-alpes, France11-50 Employees
ENYO Pharma is developing innovative therapeutics based on fibrolytic and anti-inflammatory properties for diseases with impaired kidney function. The company is conducting Phase 2 trials with its lead compound Vonafexor in Chronic Kidney Diseases (CKD) and rare kidney disease such as Alport syndrome.